Showing 3401-3410 of 3844 results for "".
- Alma Rolls Out Opus Plasmahttps://practicaldermatology.com/news/alma-rolls-out-opus-plasma/2460264/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Get to Know the Newly Restructured Crown Laboratorieshttps://practicaldermatology.com/news/get-to-know-the-newly-restructured-crown-laboratories/2460256/Crown Laboratories has restructured its commercial operations business units as it continues to elevate its new “Skin Science for Life” commitment. For the past two years, Crown says it has been dedicated to transforming its Northeast Tennessee operations into a global skinc
- DermWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://practicaldermatology.com/news/dermwire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2460244/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- Ortho Dermatologics Expands Solta Medical Team with New Hireshttps://practicaldermatology.com/news/ortho-dermatologics-expands-solta-medical-team-with-new-hires/2460237/Ortho Dermatologics is staffing up its Solta Medical business unit. The new appointments include the following: Liz Newman, General Manager, Solta, North America Newman first joined Solta in January 2018 as se
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- NavaDerm Partners Adds Dan Wechsler as Executive Chairmanhttps://practicaldermatology.com/news/navaderm-partners-adds-dan-wechsler-as-executive-chairman/2460225/Dan Wechsler is the new Executive Chairman of NavaDerm Partners, a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm. Wechs
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen
- Cassiopea Enrolls First Patient in Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Femaleshttps://practicaldermatology.com/news/cassiopea-enrolls-first-patient-in-phase-ii-trial-of-clascoterone-solution-for-the-treatment-of-androgenetic-alopecia-in-females/2460215/After receiving approval from the German Authority BfArM and the coordinating ethical committee, Cassiopea SpA is now enrolling the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in fema
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con